Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th - 16th, 2020.


GlobeNewswire Inc | Oct 9, 2020 08:00AM EDT

October 09, 2020

AUSTIN, Texas, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th - 16th, 2020.

Aspira Womens Health is scheduled to present on Wednesday, October 14 at 11:30-11:55 am EST, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay. Registration to view a webcast of the presentation can be found at: https://www.webcaster4.com/Webcast/Page/2134/37960

To receive additional information, request an invitation or to schedule a one-on-one meeting, please register at https://microcaprodeo.com/.

About Aspira Womens Health Inc.Aspira Womens Health, Inc. (formerly known as, Vermillion Inc.,Nasdaq:VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.OVA1plus includes our FDA-cleared products, OVA1and OVERAto detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXTMtesting offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development are OVANEXTMand EndoCheckTM.Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC